Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options for the other subtypes have also improved. The evidence base for what is currently the only immunomodulatory therapy for primary chronic progressive MS (PPMS) has recently been expanded by several new studies.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Subtype-specific risks and implications for neurological care
Suicidal tendencies in dementia
- Study report: Hidradenitis suppurativa
Comparison of rifampicin monotherapy with clindamycin/rifampicin combination
- From symptom to diagnosis
Oncology – Prostate carcinoma
- Stress-hyperglycemia quotient and machine learning
Prediction of mortality after heart surgery
- Supply models in Switzerland
Health 2040 research project
- Pathogenesis, diagnostics and therapeutic interventions
Sarcopenia in Parkinson’s disease
- Casuistry
63-year-old with tracheobronchopathia osteoplastica
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline